Manuscripts and Publications

Publication
Esther CR, O'Neal WK, Anderson WH, Kesimer M, Ceppe A, Doerschuk CM, Alexis NE, Hastie AT, R Barr G, Bowler RP et al..  2022.  Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.. Chest. 161(5):1239-1249.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, R Barr G, Bleecker E, Cooper CB, Couper D et al..  2018.  Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Respir Res. 19(1):178.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, Lee CHyun, R Barr G, Bleecker E, Cooper CB et al..  2019.  Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS).. Respir Res. 20(1):153.
Izquierdo M, Marion CR, Genese F, Newell JD, O'Neal WK, Li X, Hawkins GA, Barjaktarevic I, R Barr G, Christenson S et al..  2023.  Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History.. Chronic Obstr Pulm Dis. 10(3):199-210.
Barjaktarevic I, Cooper CB, Shing T, Buhr RG, Hoffman EA, Woodruff PG, M Drummond B, Kanner RE, Han MK, Hansel NN et al..  2023.  Impact of Marijuana Smoking on COPD Progression in a Cohort of Middle-Aged and Older Persons.. Chronic Obstr Pulm Dis. 10(3):234-247.
Zhang WZ, Oromendia C, Kikkers SAnn, Butler JJ, O'Beirne S, Kim K, O'Neal WK, Freeman CM, Christenson SA, Peters SP et al..  2020.  Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.. Sci Rep. 10(1):10562.
Turnier L, Eakin M, Woo H, Dransfield M, Parekh T, Krishnan JA, Kanner R, Cooper CB, Woodruff PG, Wise R et al..  2021.  The influence of social support on COPD outcomes mediated by depression.. PLoS One. 16(3):e0245478.
Hill AC, Guo C, Litkowski EM, Manichaikul AW, Yu B, Konigsberg IR, Gorbet BA, Lange LA, Pratte KA, Kechris KJ et al..  2023.  Large scale proteomic studies create novel privacy considerations. Sci Rep. 13(1):9254.
Li F, Choi J, Zou C, Newell JD, Comellas AP, Lee CHyun, Ko H, R Barr G, Bleecker ER, Cooper CB et al..  2021.  Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images.. Sci Rep. 11(1):4916.
McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HAnees, Barjaktarevic I, R Barr G, Bleecker ER, Boscardin J, Bowler RP et al..  2023.  Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.. JAMA. 330(5):442-453.
Zou C, Li F, Choi J, Haghighi B, Choi S, Rajaraman PK, Comellas AP, Newell JD, Lee CHyun, R Barr G et al..  2021.  Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Int J Chron Obstruct Pulmon Dis. 16:1477-1496.
Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, M Drummond B et al..  2018.  Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS.. PLoS One. 13(4):e0194924.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Wang JM, Labaki WW, Murray S, Martinez FJ, Curtis JL, Hoffman EA, Ram S, Bell AJ, Galbán CJ, Han MK et al..  2023.  Machine learning for screening of at-risk, mild and moderate COPD patients at risk of FEV decline: results from COPDGene and SPIROMICS.. Front Physiol. 14:1144192.
Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, M Drummond B, R Barr G et al..  2018.  Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Chronic Obstr Pulm Dis. 5(1):46-56.
J Wells M, Xing D, Viera L, Burkes RM, Wu Y, Bhatt SP, Dransfield MT, Couper DJ, O'Neal W, Hoffman EA et al..  2019.  The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS.. Respir Res. 20(1):254.
Gillenwater LA, Kechris KJ, Pratte KA, Reisdorph N, Petrache I, Labaki WW, O'Neal W, Krishnan JA, Ortega VE, DeMeo DL et al..  2021.  Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema.. Metabolites. 11(3)
Godbole S, Labaki WW, Pratte KA, Hill A, Moll M, Hastie AT, Peters SP, Gregory A, Ortega VE, Demeo D et al..  2022.  A Metabolomic Severity Score for Airflow Obstruction and Emphysema.. Metabolites. 12(5)
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.
Kesimer M, Smith BM, Ceppe A, Ford AA, Anderson WH, R Barr G, O'Neal WK, Boucher RC.  2018.  Mucin Concentrations and Peripheral Airway Obstruction in Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 198(11):1453-1456.
Shrine N, Guyatt AL, A Erzurumluoglu M, Jackson VE, Hobbs BD, Melbourne CA, Batini C, Fawcett KA, Song K, Sakornsakolpat P et al..  2019.  New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet. 51(3):481-493.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Paulin LM, Smith BM, Koch A, Han ML, Hoffman EA, Martinez C, Ejike C, Blanc PD, Rous J, R Barr G et al..  2018.  Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(12):1411-1419.

Pages